Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings
| Autor: | Francesca Ceccherini-Silberstein, Miriam Lichtner, Ada Bertoli, Manuela Colafigli, Franco Maggiolo, Ilaria Mastrorosa, Alessandra Vergori, Lidia Gazzola, Massimo Andreoni, Antonio Di Biagio, Carlo Federico Perno, Valeria Micheli, Caterina Gori, Daniele Armenia, Roberta Gagliardini, Giuliano Rizzardini, Cristina Mussini, Alberto Giannetti, Bianca Bruzzone, Yagai Bouba, Andrea Antinori, Antonella d'Arminio Monforte, Valentina Mazzotta, Anna Paola Callegaro, Vanni Borghi, Maria Mercedes Santoro, William Gennari |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Antiretroviral therapy
Drug resistance HIV-1 Integrase inhibitors Virological response Drug Resistance Viral Humans Raltegravir Potassium Viral Load Anti-HIV Agents HIV Infections HIV Integrase HIV Integrase Inhibitors 0301 basic medicine medicine.medical_specialty Settore MED/17 - Malattie Infettive 030106 microbiology Integrase inhibitor Viremia Settore MED/07 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Virology Internal medicine medicine Viral 030212 general & internal medicine Elvitegravir business.industry medicine.disease Raltegravir Regimen Infectious Diseases chemistry Dolutegravir business medicine.drug |
| Popis: | Virological response and resistance profile were evaluated in drug-naïve patients starting their first-line integrase inhibitors (INIs)-based regimen in a clinical setting.Virological success (VS) and virological rebound (VR) after therapy start were assessed by survival analyses. Drug-resistance was evaluated at baseline and at virological failure.Among 798 patients analysed, 38.6 %, 27.1 % and 34.3 % received raltegravir, elvitegravir and dolutegravir, respectively. Baseline resistance to NRTIs, NNRTIs, PIs and INIs was: 3.9 %, 13.9 %, 1.6 % and 0.5 %, respectively. Overall, by 12 months of treatment, the probability of VS was 95 %, while the probability of VR by 36 months after VS was 13.1 %. No significant differences in the virological response were found according to the INI used. The higher pre-therapy viremia strata was (100,000 vs. 100,000-500,000 vs.500,000 copies/mL), lower was the probability of VS (96.0 % vs. 95.2 % vs. 91.1 %, respectively, P0.001), and higher the probability of VR (10.2 % vs. 15.8 % vs. 16.6 %, respectively, P = 0.010). CD4 cell count200 cell/mmOur findings confirm that patients receiving an INI-based first-line regimen achieve and maintain very high rates of VS in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|